Unraveling the molecular landscape and therapeutic strategies for acute kidney injury: insights from transcriptomics, network pharmacology, virtual screening, and in vitro experiments - PubMed
3 days ago
- #Acute kidney injury
- #Drug repositioning
- #Network pharmacology
- Acute kidney injury (AKI) lacks effective early diagnostic markers and targeted therapies.
- Integrated multi-omics and network pharmacology identified key pathways: inflammation, oxidative stress, and energy metabolism.
- Three hub genes—ACO2, FBP1, and PFKL—were prioritized using CytoHubba and MCODE.
- Single-cell RNA sequencing revealed expression patterns and cellular specificity of hub genes.
- A miRNA-hub gene regulatory network was constructed to explore miRNA-based therapies.
- Molecular docking identified Ajmaline, Cimetidine, and Tretinoin as potential repurposing drugs for AKI.
- Knockout mouse models and in vitro experiments provided physiological evidence for core targets.
- The study provides a multi-layered framework for AKI biomarker prioritization and therapeutic strategies.